[Faculty] Upcoming NIH RADx-UP Initiative Funding Opportunities

[Antin, Parker B - (pba)]

Dear CALS Faculty,

The NIH has announced four funding opportunities related to COVID-19 testing access and uptake. Please feel free to contact me if you would like to discuss any of these opportunities.

Best Regards,

Parker

Parker B. Antin, Ph.D.
Associate Vice President for Research
Division of Agriculture, Life and Veterinary Sciences, and Cooperative Extension
Associate Dean for Research
College of Agriculture and Life Sciences
Professor
Department of Cellular and Molecular Medicine
College of Medicine

The University of Arizona
Forbes Building, Room 314 | 1140 E. South Campus Drive
P.O. Box 210036 | Tucson, AZ 85721-0036
Office:  520--621-5242
Cell:  520-661-6382
pba at email.arizona.edu<mailto:pba at email.arizona.edu>













Good Morning,

I hope you are all doing well. RDS wanted to let you know that the NIH has announced a Notice of Intent to Publish four COVID-19 funding opportunities. Feel free to distribute to your faculty. Please find further information below, and let RDS know if you are interested as we may be able to offer proposal development support.

Best,
Bekkah

///

The National Institutes of Health (NIH) has released a Notice of Intent to Publish<https://grants.nih.gov/grants/guide/notice-files/NOT-OD-21-064.html> forecasting four upcoming funding opportunities through the Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP)<https://www.nih.gov/research-training/medical-research-initiatives/radx/radx-programs#radx-up> initiative.  These new funding opportunities will build on the research funded in summer 2020 during the Phase I of RADx-UP, which focused on increasing access to and uptake of COVID-19 diagnostic testing among underserved and vulnerable populations.  In this second phase, RADx-UP will continue this mission while also taking into account the changing diagnostic landscape for COVID-19, the continued need for behavioral mitigation strategies, and the ongoing effects of vaccination efforts.

Four announcements – two Requests for Applications (RFAs) and two Notices of Special Interest (NOSIs) – are expected to be published around April 1, 2021:

  1.  An RFA focused on “research on testing interventions to reduce COVID-19 disparities and address scientific questions on testing in the context of vaccine implementation and uptake among underserved and vulnerable populations;”
  2.  A NOSI focused on “research that expands the scope and reach of RADx-UP testing interventions to reduce COVID-19 disparities and address scientific questions on testing in the context of vaccine implementation and uptake among underserved and vulnerable populations;”
  3.  An RFA targeting “research to understand the social, ethical, and behavioral implications (SEBI) of COVID-19 testing in underserved populations;” and
  4.  A NOSI for “administrative supplements to RADx-UP Phase I projects to understand and address vaccine hesitancy and to encourage testing and vaccine uptake among underserved and vulnerable communities, collaborating with Community Engagement Alliance (CEAL) Against COVID-19 Disparities<http://www.covid19community.nih.gov/> research teams in the same geographical region, where appropriate.”

NIH anticipates that applications for these Phase II awards will be due around April 30, 2021, with award start dates as early as July 1, 2021.  More details about the number of awards to be funded and award sizes will be available when the official solicitations are published in the coming weeks.

Beyond these specific COVID-related opportunities, NIH is planning to continue the RADx program in some capacity in the months and years ahead.  NIH Director Francis Collins has pointed to RADx as one of the most unexpected yet important successes to emerge from the COVID-19 pandemic, and has indicated that NIH will incorporate the program into its broader portfolio moving forward.  The National Institute of Biomedical Imaging and Bioengineering (NIBIB), which played a leading role in the formation of RADx, is the most likely place for this program to be permanently housed, and discussions are already underway within NIH about how a permanent RADx division would function.  Lewis-Burke will continue to monitor developments related to RADx and will pass along any relevant updates as they become available.

------------------------
Bekah Coşkun, DrPH
Associate, Biomedical Sciences
Research Development Services
Research Innovation & Impact
The University of Arizona
Working Remotely. Please email me to arrange a Zoom call.

Parker B. Antin, Ph.D.
Associate Vice President for Research
Division of Agriculture, Life and Veterinary Sciences, and Cooperative Extension
Associate Dean for Research
College of Agriculture and Life Sciences
Professor
Department of Cellular and Molecular Medicine
College of Medicine

The University of Arizona
Forbes Building, Room 314 | 1140 E. South Campus Drive
P.O. Box 210036 | Tucson, AZ 85721-0036
Office:  520--621-5242
Cell:  520-661-6382
pba at email.arizona.edu<mailto:pba at email.arizona.edu>










-------------- next part --------------
An HTML attachment was scrubbed...
URL: <https://list.cals.arizona.edu/pipermail/faculty/attachments/20210329/d8e6edbc/attachment.htm>